Core Viewpoint - Junshi Biosciences (01877) has seen a nearly 3% increase in stock price, currently trading at 25.14 HKD, with a transaction volume of 5.42 million HKD, driven by strong revenue growth primarily from its drug Toripalimab (Tuoyi) [1] Group 1: Revenue Growth - Junshi Biosciences' revenue growth is centered around Toripalimab, which is expected to generate approximately 1.495 billion CNY in sales in the domestic market by the third quarter of 2025, representing a year-on-year increase of about 40% [1] - As of the third quarter of 2025, Toripalimab has received approval for 12 indications in China, with 10 of these included in the national medical insurance catalog [1] Group 2: Clinical Developments - In the third quarter of 2025, Junshi Biosciences' key pipeline candidate JS207 (a PD-1/VEGF dual antibody) received approval from the US FDA for a Phase II/III clinical trial for neoadjuvant treatment in non-small cell lung cancer patients, while also conducting Phase II studies for colorectal cancer, triple-negative breast cancer, and liver cancer in China [1] - JS107 (Claudin18.2 ADC) has been selected for the latest breakthrough abstract (LBA) at the 2025 ESMO, where updated data from its Phase I clinical study for treating advanced solid tumors will be presented [1]

Core Viewpoint - Junshi Biosciences (01877) shows a significant revenue growth driven by its core product, Toripalimab (Tuoyi), with a projected sales revenue of approximately 1.495 billion yuan in the first three quarters of 2025, representing a year-on-year increase of about 40% [1] Group 1: Revenue and Sales Performance - The sales revenue for Toripalimab (Tuoyi) is expected to reach approximately 1.495 billion yuan by the third quarter of 2025, marking a year-on-year growth of around 40% [1] - As of the third quarter of 2025, Junshi Biosciences has received approval for 12 indications in China, with 10 of these indications included in the national medical insurance catalog [1] Group 2: Clinical Trials and Approvals - The company’s key pipeline product, JS207 (a PD-1/VEGF dual antibody), has received FDA approval for a Phase II/III clinical trial application for neoadjuvant treatment in non-small cell lung cancer patients [1] - JS207 is also undergoing Phase II studies for multiple indications, including colorectal cancer, triple-negative breast cancer, and liver cancer in China [1] - JS107 (Claudin18.2 ADC) has been selected for the latest breakthrough abstract at ESMO 2025, with updates on Phase I clinical research for treating advanced solid tumors to be announced [1]